How long does PARGY-LAD last?

The total duration of PARGY-LAD via oral is 6 hours to 8 hours. Onset typically occurs within 30 minutes to 45 minutes.

PARGY-LAD — SubstanceWiki

PARGY-LAD (N6-propargyl-6-nor-lysergic acid diethylamide, also known as 6-propargyl-6-nor-LSD) is a synthetic psychedelic of the lysergamide family. It is structurally related to AL-LAD (6-allyl-6-nor-LSD) but features a propargyl group (containing a terminal alkyne) at the N6 position rather than AL-LAD's allyl group (terminal alkene). This structural relationship makes PARGY-LAD the alkyne analog of AL-LAD, with the propargyl group's triple bond geometry producing different steric and electronic properties at the lysergamide receptor binding interface.

PARGY-LAD is one of the rarer and less documented lysergamide research chemicals. Community experience is limited, making characterization of its subjective effects less certain than for better-studied compounds. Available reports describe an experience broadly similar to AL-LAD — shorter duration than LSD (approximately 6–9 hours), visually rich, and somewhat lighter in character than LSD — with the propargyl substitution possibly contributing subtle differences in quality that are difficult to characterize from sparse data. The compound has attracted interest as one of the few truly distinct direct-acting (non-prodrug) lysergamide analogs in the research chemical market.

Given the very limited community knowledge base, extreme caution with initial doses is warranted for PARGY-LAD. Dose-response relationships have not been formally characterized, and extrapolation from AL-LAD or LSD data must be made conservatively. Testing with Ehrlich reagent is essential, and all standard lysergamide contraindications apply.

How It Feels

Information about PARGY-LAD comes from a very small pool of human experience, and what follows reflects the limited reports available. The onset is slow and uncertain, arriving over thirty to sixty minutes with an ambiguous collection of physical signals: a mild tightening in the stomach, a subtle shift in body temperature, and a vague sense that something is changing at the periphery of consciousness.

The physical character is unremarkable but present. There is a moderate body load, neither comfortable nor distressing, that settles primarily in the abdomen and lower back. A mild stimulation keeps the body alert without producing restlessness. The overall physical profile occupies a middle ground, more pronounced than the gentlest lysergamides but far less demanding than ETH-LAD or LSA. Tactile sensitivity increases slightly, and there is a gentle warmth that spreads through the torso.

At whatever passes for peak effect, PARGY-LAD produces a moderate visual enhancement and a mild to moderate cognitive shift. Surfaces may exhibit gentle breathing and flowing patterns, and colors gain some additional saturation. The headspace carries a contemplative quality, a tendency toward reflective thought and emotional openness, but without the intensity or depth that characterizes the more potent members of the family. There is a dreamy, slightly distant quality to the experience, as though the substance is gesturing toward the full lysergamide territory without fully committing to the journey.

The offset is gradual and gentle. Effects taper over several hours, leaving a mild afterglow of slightly enhanced perception and a quiet, reflective mood. The rarity of this substance means that the contours of its experience remain only partially mapped, each report adding detail to a portrait that is still largely sketched in outline. What is clear is that PARGY-LAD occupies a quiet corner of the lysergamide family, offering a moderate and somewhat indistinct psychedelic experience that is more notable for its scarcity than for any single defining characteristic.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(15)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...

Cognitive & Perceptual Effects

Visual(16)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...

Detection Methods

Urine Detection

PARGY-LAD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.

Blood and Serum Detection

Blood detection windows for PARGY-LAD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.

Standard Drug Panel Inclusion

PARGY-LAD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.

Confirmatory Methods

When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.

Reagent Testing (Harm Reduction)

For harm reduction identification, the Ehrlich reagent is the primary tool for PARGY-LAD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Acute Toxicity

No formal toxicological data exist for PARGY-LAD. By structural analogy to AL-LAD and LSD, acute toxicity is expected to be very low. No fatalities attributable to PARGY-LAD have been documented.

Cardiovascular Effects

Sympathomimetic effects consistent with the lysergamide class: mild tachycardia, blood pressure elevation, mydriasis. Contraindicated with cardiovascular disease.

Psychological Risks

Acute anxiety and panic — dose-dependent; more uncertain given sparse experience data
Psychosis induction — absolute contraindication with history of schizophrenia or bipolar I disorder
HPPD — risk with any serotonergic psychedelic

Contraindications

Personal or family history of psychosis or bipolar disorder; lithium, MAOI, antipsychotic, or tramadol use; cardiovascular disease.

Overdose

No documented pharmacological overdoses. Benzodiazepines for acute distress.

Addiction Potential

not habit-forming

Overdose Information

Fatal overdose from PARGY-LAD alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.

However, psychological emergencies can occur and require appropriate response:

Severe anxiety, panic, or psychotic episodes
Dangerous behavior due to impaired reality testing
Self-harm in the context of a distressing experience

Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.

Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.

Full	almost immediately after ingestion
Half	5-7 days
Zero	14 days

PARGY-LAD

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(15)

Cognitive & Perceptual Effects

Visual(16)

Pharmacology

Mechanism of Action

Receptor Targets

Pharmacokinetics

Tolerance

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Origins

Research Chemical Market

Legal Status

Harm Reduction

Testing

Dosing

Set and Setting

Dangerous Combinations

Emergency Protocol

Toxicity & Safety

Acute Toxicity

Cardiovascular Effects

Psychological Risks

Contraindications

Overdose

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (3)

See Also

Similar by Effects

Same Class

References (6)

Frequently Asked Questions

Cognitive(17)

Auditory(2)

Multi-sensory(1)

Transpersonal(3)